Cargando…
Updates on the Treatment of Erythrodermic Psoriasis
Erythrodermic psoriasis (EP) is a rare variant of psoriasis, which is potentially life threatening and often resistant to conventional therapy. Biologics have revolutionized the treatment of plaque-type psoriasis, and shown promise in EP. However, due to the lack of head-to-head studies and the rari...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200157/ https://www.ncbi.nlm.nih.gov/pubmed/34136373 http://dx.doi.org/10.2147/PTT.S288345 |
_version_ | 1783707545655836672 |
---|---|
author | Lo, Yang Tsai, Tsen-Fang |
author_facet | Lo, Yang Tsai, Tsen-Fang |
author_sort | Lo, Yang |
collection | PubMed |
description | Erythrodermic psoriasis (EP) is a rare variant of psoriasis, which is potentially life threatening and often resistant to conventional therapy. Biologics have revolutionized the treatment of plaque-type psoriasis, and shown promise in EP. However, due to the lack of head-to-head studies and the rarity of EP, no high level evidence-based treatment guidelines for EP have been established, and the evidence of treatment of EP is limited to case reports or small case series. Here, we present a narrative review focusing on the up-to-date information for the treatment of EP. |
format | Online Article Text |
id | pubmed-8200157 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-82001572021-06-15 Updates on the Treatment of Erythrodermic Psoriasis Lo, Yang Tsai, Tsen-Fang Psoriasis (Auckl) Review Erythrodermic psoriasis (EP) is a rare variant of psoriasis, which is potentially life threatening and often resistant to conventional therapy. Biologics have revolutionized the treatment of plaque-type psoriasis, and shown promise in EP. However, due to the lack of head-to-head studies and the rarity of EP, no high level evidence-based treatment guidelines for EP have been established, and the evidence of treatment of EP is limited to case reports or small case series. Here, we present a narrative review focusing on the up-to-date information for the treatment of EP. Dove 2021-06-09 /pmc/articles/PMC8200157/ /pubmed/34136373 http://dx.doi.org/10.2147/PTT.S288345 Text en © 2021 Lo and Tsai. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Lo, Yang Tsai, Tsen-Fang Updates on the Treatment of Erythrodermic Psoriasis |
title | Updates on the Treatment of Erythrodermic Psoriasis |
title_full | Updates on the Treatment of Erythrodermic Psoriasis |
title_fullStr | Updates on the Treatment of Erythrodermic Psoriasis |
title_full_unstemmed | Updates on the Treatment of Erythrodermic Psoriasis |
title_short | Updates on the Treatment of Erythrodermic Psoriasis |
title_sort | updates on the treatment of erythrodermic psoriasis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200157/ https://www.ncbi.nlm.nih.gov/pubmed/34136373 http://dx.doi.org/10.2147/PTT.S288345 |
work_keys_str_mv | AT loyang updatesonthetreatmentoferythrodermicpsoriasis AT tsaitsenfang updatesonthetreatmentoferythrodermicpsoriasis |